Amidst the media storm and calls for investigation swirling around Mylan regarding the price of their EpiPen® epinephrine auto-injector, the company issued a press release outlining a series of consumer facing initiatives to make the device more affordable.
In case you missed it, here are the four initiatives gleaned from the press release that Mylan has committed to so far, along with the relevant links and comments.
- The company will immediately offer a savings card for up to $300 that will reduce out of pocket expenses by 50%. This benefit is only for people with prescription coverage. You can learn more about eligibility and apply for this card by clicking here.
- The company will raise eligibility for their patient assistance program to 400% of the federal poverty level. As an example, a family of four making up to $97,200 will pay nothing out of pocket for their EpiPen auto-injectors. You can apply for this benefit by clicking here.
- The company will continue its EpiPen4Schools® program which provides free, stock EpiPens. Make sure your child’s school participates in the program. Schools can apply by clicking here.
- Mylan will provide a means to order EpiPens directly from the company, further reducing the cost. We will provide more information on this new capability as it becomes available from the company.
The hope is that these steps will move us closer to the ideal of every single person in need of epinephrine auto-injectors being able to afford them.
What the press release did not address is how the cost of the device will change for insurers. This has an indirect effect on the subsequent cost of healthcare insurance acquired via employers, directly, or via the exchanges established under the Patient Protection and Affordable Care Act (ACA or “Obama Care”.) We will report on this aspect once we have more information.